XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.4.0.3

Segment Information | 9 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2016 | Apr. 30, 2015
Segment Reporting [Abstract] |  |
Segment Reporting Disclosure [Text Block] | ## Note 8. Segment Information The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2015, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):
Three Months Ended January 31, 2016 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 416 |  |  | $ | 2,136 |  |  | $ | — |  |  | $ | 2,552 |
Direct cost of services |  |  | (479 | ) |  |  | (1,624 | ) |  |  | — |  |  |  | (2,103 | )
Sales and marketing costs |  |  | (183 | ) |  |  | (569 | ) |  |  | — |  |  |  | (752 | )
Other operating expenses |  |  | — |  |  |  | (950 | ) |  |  | (553 | ) |  |  | (1,503 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (567 | ) |  |  | (567 | )
Segment profit (loss) |  | $ | (246 | ) |  | $ | (1,007 | ) |  | $ | (1,120 | ) |  | $ | (2,373 | )
Three Months Ended January 31, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 453 |  |  | $ | 1,376 |  |  | $ | — |  |  | $ | 1,829 |
Direct cost of services |  |  | (672 | ) |  |  | (1,300 | ) |  |  | — |  |  |  | (1,972 | )
Sales and marketing costs |  |  | (366 | ) |  |  | (613 | ) |  |  | — |  |  |  | (979 | )
Other operating expenses |  |  | — |  |  |  | (1,028 | ) |  |  | (612 | ) |  |  | (1,640 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (657 | ) |  |  | (657 | )
Segment profit (loss) |  | $ | (585 | ) |  | $ | (1,565 | ) |  | $ | (1,269 | ) |  | $ | (3,419 | )
Nine Months Ended January 31, 2016 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,387 |  |  | $ | 6,958 |  |  | $ | — |  |  | $ | 8,345 |
Direct cost of services |  |  | (1,634 | ) |  |  | (4,654 | ) |  |  | — |  |  |  | (6,288 | )
Sales and marketing costs |  |  | (716 | ) |  |  | (1,800 | ) |  |  | — |  |  |  | (2,516 | )
Other operating expenses |  |  | — |  |  |  | (2,755 | ) |  |  | (2,463 | ) |  |  | (5,218 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,090 | ) |  |  | (2,090 | )
Segment profit (loss) |  | $ | (963 | ) |  | $ | (2,251 | ) |  | $ | (4,553 | ) |  | $ | (7,767 | )
Nine Months Ended January 31, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,245 |  |  | $ | 4,377 |  |  | $ | — |  |  | $ | 5,622 |
Direct cost of services |  |  | (2,171 | ) |  |  | (3,205 | ) |  |  | — |  |  |  | (5,376 | )
Sales and marketing costs |  |  | (1,243 | ) |  |  | (1,650 | ) |  |  | — |  |  |  | (2,893 | )
Other operating expenses |  |  | — |  |  |  | (3,490 | ) |  |  | (2,413 | ) |  |  | (5,903 | )
Stock-based compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,284 | ) |  |  | (2,284 | )
Segment profit (loss) |  | $ | (2,169 | ) |  | $ | (3,968 | ) |  | $ | (4,697 | ) |  | $ | (10,834 | )
| (1) | Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.
| ## Note 10. Business Segment Information The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
Year Ended April 30, 2015 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 1,663 |  |  | $ | 7,200 |  |  | $ | — |  |  | $ | 8,863 |
Direct cost of services |  |  | (2,711 | ) |  |  | (4,877 | ) |  |  | — |  |  |  | (7,588 | )
Sales and marketing costs |  |  | (1,514 | ) |  |  | (2,208 | ) |  |  | — |  |  |  | (3,722 | )
Other operating expenses |  |  | — |  |  |  | (4,493 | ) |  |  | (3,136 | ) |  |  | (7,729 | )
Stock compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (3,162 | ) |  |  | (3,162 | )
Segment profit (loss) |  | $ | (2,562 | ) |  | $ | (4,378 | ) |  | $ | (6,298 | ) |  | $ | (13,238 | )
Year Ended April 30, 2014 |  | Personalized Oncology Solutions (POS) |  | Translational Oncology Solutions (TOS) |  | Unallocated Corporate Overhead |  | Consolidated
Net revenue |  | $ | 2,264 |  |  | $ | 9,286 |  |  | $ | — |  |  | $ | 11,550 |
Direct cost of services |  |  | (2,667 | ) |  |  | (3,496 | ) |  |  | — |  |  |  | (6,163 | )
Sales and marketing costs |  |  | (1,723 | ) |  |  | (1,080 | ) |  |  | — |  |  |  | (2,803 | )
Other operating expenses |  |  | — |  |  |  | (2,209 | ) |  |  | (3,828 | ) |  |  | (6,037 | )
Stock compensation expense(1) |  |  | — |  |  |  | — |  |  |  | (2,807 | ) |  |  | (2,807 | )
Segment loss |  | $ | (2,126 | ) |  | $ | 2,501 |  |  | $ | (6,635 | ) |  | $ | (6,260 | )
| (1) | Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration